Johnson & Johnson Aims To Regain Remicade Rights

Law360, New York (May 21, 2009, 12:00 AM EDT) -- Johnson & Johnson plans to head to arbitration to seek the return of its full rights to market and sell arthritis treatment Remicade from Schering-Plough Corp. now that Merck & Co. plans to acquire the pharmaceutical company.

The merger plan allows Johnson & Johnson to terminate a deal with Schering-Plough that gives the Kenilworth, N.J.-based company the rights to distribute Remicade and related products in markets outside the U.S., Johnson & Johnson said Thursday.

In a regulatory filing with the U.S. Securities and Exchange Commission on...
To view the full article, register now.